Nanoparticles decorated with two functional peptides — T7 for brain targeting and R9 for cell penetration — improved blood-brain barrier crossing and increased glioblastoma cell death up to 6.5-fold compared to the drug alone.
2.3-6.5x more cell deathDual-peptide (T7/R9) functionalized nanoparticles enhanced glioblastoma cell apoptosis by 2.3 to 6.5-fold compared to free palbociclib, with the dual-peptide formulation outperforming all others.
What the researchers found
PLGA-PEG nanoparticles were functionalized with T7 targeting peptide and R9 cell-penetrating peptide, yielding particles of 168-186 nm with high drug loading efficiency (>80%). In a transwell BBB model using bEnd.3 cells, the penetration efficiency ranked: T7/R9 dual-peptide NPs > T7-peptide NPs > peptide-free NPs > free palbociclib.
The dual-peptide modified nanoparticles enhanced U87-MG glioblastoma cell apoptosis by 2.3 to 6.5-fold relative to free palbociclib, with the dual-peptide formulation being the most effective. The sequential mechanism — BBB penetration facilitated by T7/R9, followed by targeting to glioma cells — demonstrated effective cytotoxicity and promoted cell death.
Why it matters
Glioblastoma is nearly always fatal partly because the blood-brain barrier prevents most drugs from reaching the tumor. Palbociclib is already proven effective against glioma cells in the lab but can't get past the BBB in sufficient quantities. This dual-peptide nanoparticle approach solves both problems — crossing the BBB and enhancing drug uptake into cancer cells — using two peptides with complementary functions.
How the study worked
PLGA-PEG nanoparticles were prepared and functionalized with T7 peptide, R9 peptide, or both. Palbociclib was loaded and encapsulation efficiency measured. BBB penetration was assessed using a bEnd.3 cell transwell model. Cytotoxicity and apoptosis were evaluated in U87-MG glioblastoma cells. Cellular uptake was compared across formulations.
What this study cannot tell us
This was entirely an in vitro study using cell-based BBB models, which are simplified representations of the actual blood-brain barrier. No animal studies were conducted to validate BBB crossing in vivo. The bEnd.3 transwell model lacks important BBB features like astrocyte interactions and blood flow. Long-term stability, pharmacokinetics, and biodistribution of the nanoparticles are unknown. Off-target effects of the cell-penetrating R9 peptide on healthy brain tissue were not assessed.
How to read the evidence
This is an in vitro proof-of-concept study using cell-based models. The results are promising for nanoparticle design but have not been validated in animal models or clinical settings. The evidence is at the earliest preclinical stage.
When this study was published
Published in 2023, this is recent research in the active field of peptide-mediated brain drug delivery. Multiple groups are working on similar dual-functionalized nanoparticle approaches for brain cancer.
The bigger picture
Peptide-functionalized nanoparticles represent a major strategy for brain drug delivery. The concept of using multiple peptides with different functions (BBB crossing + cell penetration) on a single nanoparticle is a design principle that could be applied broadly — not just for brain cancer but for any brain disease where drug delivery is the bottleneck. The approach also demonstrates how repurposing FDA-approved drugs (palbociclib for breast cancer) with improved delivery could expand their therapeutic applications.
Questions still open
- Do these dual-peptide nanoparticles effectively cross the intact blood-brain barrier in animal models and accumulate in brain tumors?
- Could the R9 cell-penetrating peptide cause unwanted drug delivery to healthy brain cells, leading to neurotoxicity?
- Would this dual-peptide nanoparticle platform work for delivering other brain cancer drugs beyond palbociclib?
Common questions
Why is it so hard to get drugs into the brain?
What do the two peptides on these nanoparticles do?
Read the original research
Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles.
Pharmaceutics, 15(10)
Citation
Lo, Yu-Chen; Lin, Wen-Jen. (2023). Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles.. Pharmaceutics, 15(10). https://doi.org/10.3390/pharmaceutics15102429